• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.用于BRCT-磷蛋白相互作用抑制剂的双荧光团定量高通量筛选
Anal Biochem. 2008 Apr 1;375(1):60-70. doi: 10.1016/j.ab.2007.11.039. Epub 2007 Dec 5.
2
High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.用于鉴定乳腺癌基因1的BRCT结构域小分子抑制剂的高通量荧光偏振分析。
Anal Biochem. 2006 May 1;352(1):135-41. doi: 10.1016/j.ab.2006.01.025. Epub 2006 Feb 3.
3
The BRCT domain is a phospho-protein binding domain.BRCT结构域是一种磷酸化蛋白结合结构域。
Science. 2003 Oct 24;302(5645):639-42. doi: 10.1126/science.1088753.
4
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression.BRCA1的C末端(BRCT)结构域在体内与CtIP相互作用,CtIP是一种与转录抑制的CtBP途径相关的蛋白质。
J Biol Chem. 1998 Sep 25;273(39):25388-92. doi: 10.1074/jbc.273.39.25388.
5
Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites.BRCA1-BRCT/Abraxas复合物的结构揭示了DNA损伤位点处磷酸化依赖性的BRCT二聚化
Mol Cell. 2016 Feb 4;61(3):434-448. doi: 10.1016/j.molcel.2015.12.017. Epub 2016 Jan 14.
6
A high throughput fluorescence polarization assay for inhibitors of the GoLoco motif/G-alpha interaction.一种用于检测GoLoco基序/Gα相互作用抑制剂的高通量荧光偏振检测法。
Comb Chem High Throughput Screen. 2008 Jun;11(5):396-409. doi: 10.2174/138620708784534770.
7
Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.与癌症相关的BRCA1-BRCT错义变体的特征及其与磷蛋白靶点的相互作用。
Proteins. 2009 Nov 1;77(2):464-76. doi: 10.1002/prot.22460.
8
Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.BRCA1-CtIP复合物对细胞周期检查点控制的结构基础。
Biochemistry. 2005 Aug 23;44(33):10941-6. doi: 10.1021/bi0509651.
9
Interactions between BRCT repeats and phosphoproteins: tangled up in two.BRCT重复序列与磷酸化蛋白之间的相互作用:纠结于二者之中。
Trends Biochem Sci. 2004 Nov;29(11):579-85. doi: 10.1016/j.tibs.2004.09.010.
10
BRCA1 tumor suppressor network: focusing on its tail.BRCA1 肿瘤抑制器网络:关注其尾部。
Cell Biosci. 2012 Feb 27;2(1):6. doi: 10.1186/2045-3701-2-6.

引用本文的文献

1
BRCT Domains: Structure, Functions, and Implications in Disease-New Therapeutic Targets for Innovative Drug Discovery against Infections.BRCT结构域:结构、功能及其在疾病中的意义——针对感染性疾病创新药物研发的新治疗靶点
Pharmaceutics. 2023 Jun 27;15(7):1839. doi: 10.3390/pharmaceutics15071839.
2
High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.用于抗菌药物发现的天然产物和合成分子文库的高通量筛选
Metabolites. 2023 May 2;13(5):625. doi: 10.3390/metabo13050625.
3
Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.构效关系(SAR)研究鉴定出一种调节 IKKβ 磷酸化的喹喔啉脲类似物,可用于胰腺癌治疗。
Eur J Med Chem. 2021 Oct 15;222:113579. doi: 10.1016/j.ejmech.2021.113579. Epub 2021 May 30.
4
Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design.磷配体与乳腺癌基因1(BRCA1)C末端(BRCT)的混杂结合特性:分子动力学、自由能、熵及抑制剂设计
PLoS Comput Biol. 2016 Aug 25;12(8):e1005057. doi: 10.1371/journal.pcbi.1005057. eCollection 2016 Aug.
5
Irreversible binding of an anticancer compound (BI-94) to plasma proteins.一种抗癌化合物(BI - 94)与血浆蛋白的不可逆结合。
Xenobiotica. 2015;45(10):858-73. doi: 10.3109/00498254.2015.1025250. Epub 2015 Apr 14.
6
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.小分子5'-单磷酸腺苷激活蛋白激酶(AMPK)调节剂与人类疾病
J Med Chem. 2015 Jan 8;58(1):2-29. doi: 10.1021/jm401994c. Epub 2014 Aug 28.
7
Synthetic lethal screens as a means to understand and treat MYC-driven cancers.合成致死筛选作为一种理解和治疗 MYC 驱动型癌症的方法。
Cold Spring Harb Perspect Med. 2014 Mar 1;4(3):a014209. doi: 10.1101/cshperspect.a014209.
8
Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.靶向治疗致癌调控因子的小分子药物策略展望。
J Cell Biochem. 2014 Apr;115(4):611-24. doi: 10.1002/jcb.24704.
9
High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of AMSH deubiquitinase activity.高通量兼容的荧光共振能量转移测定法,用于鉴定 AMSH 去泛素化酶活性的小分子抑制剂。
Anal Biochem. 2013 Sep 1;440(1):71-7. doi: 10.1016/j.ab.2013.05.017. Epub 2013 Jun 5.
10
The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides.Cbl(TKB)结合肽设计中构象限制的悖论。
Sci Rep. 2013;3:1639. doi: 10.1038/srep01639.

本文引用的文献

1
Compound Management for Quantitative High-Throughput Screening.用于定量高通量筛选的化合物管理
JALA Charlottesv Va. 2008 Apr;13(2):79-89. doi: 10.1016/j.jala.2007.12.004.
2
Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design.磷酸肽与BRCT结构域连接的热力学:抑制剂设计的结构最小值
J Am Chem Soc. 2007 Sep 5;129(35):10658-9. doi: 10.1021/ja0739178. Epub 2007 Aug 9.
3
CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response.CCDC98是一种参与DNA损伤反应的BRCA1-BRCT结构域结合蛋白。
Nat Struct Mol Biol. 2007 Aug;14(8):710-5. doi: 10.1038/nsmb1277. Epub 2007 Jul 22.
4
CCDC98 targets BRCA1 to DNA damage sites.中国疾病预防控制中心98号蛋白将乳腺癌1号基因靶向至DNA损伤位点。
Nat Struct Mol Biol. 2007 Aug;14(8):716-20. doi: 10.1038/nsmb1279. Epub 2007 Jul 22.
5
High-throughput screening assays for the identification of chemical probes.用于鉴定化学探针的高通量筛选分析
Nat Chem Biol. 2007 Aug;3(8):466-79. doi: 10.1038/nchembio.2007.17.
6
Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response.泛素结合蛋白RAP80介导BRCA1依赖性DNA损伤反应。
Science. 2007 May 25;316(5828):1202-5. doi: 10.1126/science.1139621.
7
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.RAP80将乳腺癌1号基因(BRCA1)靶向到DNA损伤位点的特定泛素结构上。
Science. 2007 May 25;316(5828):1198-202. doi: 10.1126/science.1139516.
8
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.Abraxas和RAP80形成一种DNA损伤反应所需的BRCA1蛋白复合物。
Science. 2007 May 25;316(5828):1194-8. doi: 10.1126/science.1139476.
9
A high-throughput screen for aggregation-based inhibition in a large compound library.针对一个大型化合物库中基于聚集的抑制作用进行的高通量筛选。
J Med Chem. 2007 May 17;50(10):2385-90. doi: 10.1021/jm061317y. Epub 2007 Apr 21.
10
A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase.一种新型结核分枝杆菌泛酸合成酶抑制剂。
J Biomol Screen. 2007 Feb;12(1):100-5. doi: 10.1177/1087057106296484. Epub 2006 Dec 14.

用于BRCT-磷蛋白相互作用抑制剂的双荧光团定量高通量筛选

Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.

作者信息

Simeonov Anton, Yasgar Adam, Jadhav Ajit, Lokesh G L, Klumpp Carleen, Michael Sam, Austin Christopher P, Natarajan Amarnath, Inglese James

机构信息

NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Anal Biochem. 2008 Apr 1;375(1):60-70. doi: 10.1016/j.ab.2007.11.039. Epub 2007 Dec 5.

DOI:10.1016/j.ab.2007.11.039
PMID:18158907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3389998/
Abstract

Finding specific small-molecule inhibitors of protein-protein interactions remains a significant challenge. Recently, attention has grown toward "hot spot" interactions where binding is dominated by a limited number of amino acid contacts, theoretically offering an increased opportunity for disruption by small molecules. Inhibitors of the interaction between BRCT (the C-terminal portion of BRCA1, a key tumor suppressor protein with various functions) and phosphorylated proteins (Abraxas/BACH1/CtIP), implicated in DNA damage response and repair pathways, should prove to be useful in studying BRCA1's role in cancer and in potentially sensitizing tumors to chemotherapeutic agents. We developed and miniaturized to a 1536-well format and 3-mul final volume a pair of fluorescence polarization (FP) assays using fluorescein- and rhodamine-labeled pBACH1 fragment. To minimize the effect of fluorescence artifacts and to increase the overall robustness of the screen, the 75,552 compound library members all were assayed against both the fluorescein- and rhodamine-labeled probe-protein complexes in separate but interleaved reactions. In addition, every library compound was tested over a range of concentrations following the quantitative high-throughput screening (qHTS) paradigm. Analyses of the screening results led to the selection and subsequent confirmation of 16 compounds active in both assays. Faced with a traditionally difficult protein-protein interaction assay, by performing two-fluorophore qHTS, we were able to confidently select a number of actives for further studies.

摘要

寻找蛋白质 - 蛋白质相互作用的特异性小分子抑制剂仍然是一项重大挑战。最近,人们对“热点”相互作用的关注度不断提高,在这种相互作用中,结合主要由有限数量的氨基酸接触主导,理论上为小分子干扰提供了更多机会。BRCT(乳腺癌1号基因C端区域,一种具有多种功能的关键肿瘤抑制蛋白)与磷酸化蛋白(Abraxas/BACH1/CtIP)之间的相互作用抑制剂参与DNA损伤反应和修复途径,在研究BRCA1在癌症中的作用以及使肿瘤对化疗药物敏感方面应该会很有用。我们开发了一对使用荧光素和罗丹明标记的pBACH1片段的荧光偏振(FP)测定法,并将其小型化为1536孔板形式且最终体积为3微升。为了最小化荧光假象的影响并提高筛选的整体稳健性,75552种化合物库成员均在单独但交错的反应中针对荧光素和罗丹明标记的探针 - 蛋白质复合物进行了测定。此外,按照定量高通量筛选(qHTS)模式,对每种库化合物在一系列浓度下进行了测试。对筛选结果的分析导致选择并随后确认了16种在两种测定中均有活性的化合物。面对传统上困难的蛋白质 - 蛋白质相互作用测定,通过进行双荧光团qHTS,我们能够自信地选择一些活性化合物进行进一步研究。